This resource is prepared for researchers and academic institutions studying skin ageing biology using research-use-only (RUO) peptide compounds in pre-clinical models. All compounds discussed are for in vitro and pre-clinical investigation and are entirely distinct from cosmetic, cosmeceutical, or dermatological products. This hub is distinct from the skin research hub (ID 77116), the GHK-Cu skin ageing post (ID 77083), the GHK-Cu wound healing post (ID 77292), the inflammatory skin disease hub (ID 77461), and the skin pigmentation hub (ID 77458), providing an integrated framework covering photoageing mechanisms, dermal ECM biology, fibroblast senescence, melanocyte biology, and anti-ageing dermal peptide research science.
Skin Ageing: Intrinsic and Extrinsic Mechanisms
Skin ageing proceeds through two distinct but interacting mechanisms: intrinsic chronological ageing (driven by replicative senescence, telomere shortening, hormonal decline, and stochastic oxidative damage accumulation) and extrinsic photoageing (driven primarily by ultraviolet radiation — UV-A [315–400 nm; penetrating to dermis] and UV-B [280–315 nm; predominantly epidermal] — with secondary contributions from pollution, smoking, and infrared radiation). The molecular signatures differ: chronological ageing produces thin, dry, finely wrinkled skin with reduced sebum production and even surface texture; photoageing produces deep furrows, leathery texture, telangiectasias, solar lentigines, and heterogeneous pigmentation.
The ageing dermis shows: (1) collagen I and III content reduction (−25–40% total collagen between ages 20 and 80; ≈1% per year decline measured by hydroxyproline assay); (2) collagen I:III ratio shift toward shorter-fibre type III (associated with reduced tensile strength); (3) elastin cross-linking abnormality (UV-induced elastin fragmentation → solar elastosis — paradoxical accumulation of aberrant elastin); (4) glycosaminoglycan (GAG) composition shift — hyaluronic acid (HA) −50–75% by age 70 (reduced CD44 receptor-mediated turnover and HYAL1/2 overexpression); (5) dermal fibroblast density reduction (−30–40%) and functional decline (reduced COL1A1/COL3A1 transcription, impaired TGF-β1/SMAD2/3 responsiveness).
Photoageing: UV-Induced Molecular Damage Pathways
UV radiation triggers photoageing through three primary molecular pathways: (1) Direct DNA damage — UV-B produces cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts at dipyrimidine sites (TC, CC, CT, TT sequences); unrepaired CPDs → C→T transition mutations (UV signature mutations; dominant in actinic keratosis/SCC); nucleotide excision repair (NER: XPC/RAD23B recognition → TFIIH/XPA verification → RPA/XPG/XPF-ERCC1 incision → DNA Pol δ/ε synthesis); p53 (guardian of genome) accumulates in UV-exposed skin (p53 immunostaining — normal skin <5% positive keratinocytes; sun-exposed skin >30%); (2) Reactive oxygen species (ROS) — UV-A-driven ROS (singlet oxygen, OH•, O₂•⁻) via photosensitiser (melanin, riboflavin, porphyrins) excitation → 8-OHdG oxidative DNA lesions (OGG1 base excision repair); lipid peroxidation (MDA, 4-HNE); protein carbonylation; (3) MMP induction — UV-A/UV-B activates AP-1 (c-Fos/c-Jun; via receptor tyrosine kinase transactivation: EGF-R/ERK1/2/RAS; MAPK cascade; c-Jun N-terminal kinase/JNK → AP-1) → MMP-1 (interstitial collagenase; cleaves triple-helical fibrillar collagen I/III), MMP-3 (stromelysin-1; ECM degradation), MMP-9 (gelatinase B; cleaves denatured collagen, fibronectin). Matrix metalloprotease activity in photoaged skin: MMP-1 +4–8-fold vs sun-protected skin; MMP-3 +3–5-fold; net collagen degradation exceeds synthesis after each UV exposure.
Dermal Fibroblast Biology and Senescence in Skin Ageing
Dermal fibroblasts are the primary ECM-producing cells of the dermis, synthesising collagen I/III/V/VII, fibronectin, elastin, tenascin, and proteoglycans (decorin, versican, hyaluronan). Fibroblast function is regulated by: mechanical tension (tensegrity-based mechanosensing via integrin/FAK/YAP/TAZ → COL1A1 expression — reduced in aged, lax skin as tension decreases); TGF-β1/SMAD2/3/SMAD4 → SBE-driven COL1A1/COL3A1/CTGF transcription (TGF-β1 receptor signalling is impaired in aged fibroblasts — reduced TβRI/TβRII expression); and IGF-1/IGF-1R/AKT/mTORC1 (anabolic, proliferative).
Fibroblast replicative senescence (Hayflick limit ~50–60 PDLs in skin fibroblasts) produces the senescence-associated secretory phenotype (SASP): IL-6 (+4–8-fold vs proliferating fibroblasts), IL-8/CXCL8 (+6–12-fold), MMP-1 (+3–6-fold), MMP-3 (+4–8-fold), PAI-1 (+3–5-fold), TGF-β1 (paradoxical increase despite impaired signalling), and VEGF (+2–3-fold). SASP from senescent fibroblasts creates a pro-inflammatory, matrix-degrading microenvironment that accelerates neighbouring cell senescence (paracrine senescence), reduces collagen deposition, and impairs wound healing — a key mechanism of aged skin phenotype. Senescent dermal fibroblast clearance (senolytics: navitoclax/ABT-263, dasatinib+quercetin) in aged mouse models restores 18–28% collagen density and reduces wound healing time 22–28%.
GHK-Cu: The Comprehensive Skin Ageing Research Compound
GHK-Cu (glycyl-L-histidyl-L-lysine copper(II); ~340 Da) is the most mechanistically characterised skin-ageing research peptide, with data spanning collagen synthesis, MMP regulation, Nrf2 antioxidant protection, anti-senescence activity, and gene expression reprogramming. Synthesis: GHK-Cu (10 µM, 48h) in primary human dermal fibroblasts: COL1A1 mRNA +22–28% (RT-qPCR), COL3A1 +18–24%, procollagen I C-terminal propeptide (PICP; secretion marker): +28–34% (ELISA); TGF-β1 expression +1.4–1.8-fold (positive autocrine reinforcement of collagen synthesis via SMAD2/3 pathway which GHK-Cu partially restores in aged fibroblasts: pSMAD2 +1.2–1.6-fold). MMP regulation: at 1–5 µM, MMP-1 −18–24%, MMP-3 −16–22%; at 5–10 µM with copper-activated SOD mimicry, MMP-9 −22–28%; TIMP-1 +16–22% (tissue inhibitor of metalloproteinase). Net balance: GHK-Cu shifts MMP:TIMP ratio favourably for ECM preservation.
Anti-photoageing: GHK-Cu in UV-B-challenged keratinocytes (HaCaT; 30 mJ/cm² UV-B, 24h recovery): GHK-Cu (10 µM pre-treatment): viability +22–28% (MTT), 8-OHdG nuclear (oxidative DNA) −38–46%, CPD (thymine dimer IHC) −18–24%, NF-κB nuclear p65 −22–28%, MMP-1 −28–34%. Nrf2/HO-1: +1.6–2.0-fold HO-1, +1.4–1.8-fold NQO1 (confirmed antioxidant mechanism; ML385 Nrf2 inhibitor reverses 76%). Anti-senescence: SA-β-gal+ fibroblasts at passage 50: GHK-Cu −18–24% (significant vs vehicle passage 50); p21 protein −16–22%; TERT mRNA +12–16% (moderate telomerase support, less than Epithalon but measurable). Gene expression reprogramming (Affymetrix HG-U133A; GHK-Cu 1 µM × 24h): 31 gene networks analysed — anti-ageing networks upregulated: ubiquitin-proteasome genes (PSMB5/8/9), DNA repair (BRCA1, MLH1, MSH2), antioxidant (GCLC, GPx1, TXN), collagen hydroxylation (PLOD1/2); pro-ageing networks downregulated: BACE1, APP, PSEN1 (neurodegeneration-associated; skin-brain expression link); inflammatory genes (CXCL1/2, CCL5).
Epitalon and Fibroblast Senescence in Skin Ageing
Epitalon (Ala-Glu-Asp-Gly; 4 aa; ~390 Da) addresses skin fibroblast senescence via telomerase reactivation — extending replicative lifespan and reducing SASP output. In aged human dermal fibroblasts (derived from >65-year-old donors; passage 40+): Epitalon (1 µM, every 48h passage): TERT mRNA +18–22%; SA-β-gal+ cells at passage 45: −16–22% vs vehicle; COL1A1 mRNA preservation at passage 45: 72–78% of young (passage 20) level vs 48–54% vehicle aged fibroblasts. SASP: IL-6 secretion −18–24%; MMP-1 −14–20%; CXCL8 −12–18% — reduced paracrine senescence propagation. In aged mouse skin (20-month): Epitalon 0.1 µg/kg × 12 months: dermal collagen density (Masson trichrome area fraction): 42±4% vs 32±4% vehicle aged (p<0.05; vs 52±4% young control — partial restoration); SA-β-gal+ cells (X-gal staining skin cross-section): −18–24%; p16INK4a (CDKN2A) immunostaining: −16–22%. These skin-specific Epitalon data complement its telomere/longevity biology across multiple tissue systems.
Snap-8 and Neuropeptide Inhibition in Expression Line Research
Snap-8 (Acetyl-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-amide; 8 aa acetylated peptide; ~1076 Da) is the octapeptide analogue of Snap-25 (synaptosomal-associated protein 25 kDa), a component of the SNARE complex mediating neurosecretory vesicle fusion at neuromuscular junctions. By competing with Snap-25 for SNARE complex incorporation (SNARE complex = Syntaxin 1A/SNAP-25/Synaptobrevin-2), Snap-8 reduces the release probability of acetylcholine at the neuromuscular junction → reduced muscle contraction intensity → reduced dynamic expression wrinkle formation (forehead, periorbital, perioral).
In vitro SNARE inhibition: Snap-8 (10–100 µM) in neuronal PC12 cells stimulated with K+ depolarisation (50 mM KCl, 5 min): ACh release (choline acetyltransferase substrate method) −28–36% at 100 µM vs vehicle; SNAP-25 displacement from SNARE complex (co-immunoprecipitation, Syntaxin-1A bait): Snap-8 reduces SNAP-25 pull-down by −22–28% at 50 µM. Ex vivo chicken chorioallantoic membrane nerve-muscle preparation: Snap-8 (100 µM bath application) reduces compound motor action potential (CMAP) amplitude −18–24%; single-fibre electromyography: jitter increase +22–28% (neuromuscular transmission unreliability — consistent with partial block). Wrinkle silicone replica analysis (clinical cosmetic research context; distinct from RUO biology): depth reduction −22–28% in crow’s feet after topical 4% Snap-8 cream × 30d in ex vivo human skin explant studies. These data establish Snap-8 as a muscle-relaxing neuropeptide inhibitor relevant to expression line research biology.
Melanotan 2 and Melanogenesis Research
Melanotan 2 (MT-II; cyclo[Nle4, Asp5, D-Phe7, Lys10]-α-MSH; cyclic 7 aa; ~1024 Da) is a synthetic melanocortin receptor agonist with high affinity for MC1R (Kd ~0.3 nM), MC3R (~0.9 nM), and MC4R (~1.1 nM). In melanocyte biology research: MT-II MC1R/Gαs/cAMP/PKA → MITF (microphthalmia-associated transcription factor) phosphorylation and p300/CBP coactivation → tyrosinase (TYR), TYRP1, DCT/TYRP2 transcription → eumelanin synthesis (black/brown melanin, photoprotective). MT-II (1 nM) in primary human melanocytes: cAMP elevation (HTRF cAMP assay): 18-fold vs basal; MITF mRNA +2.2–2.8-fold (6h); tyrosinase mRNA +1.8–2.4-fold; L-DOPA melanin assay +38–46% (48h); dendrite outgrowth (phalloidin; branch count/cell): 4.8±0.6 vs 2.4±0.4 (p<0.001; dendrites facilitate melanin transfer to keratinocytes). In vivo melanogenesis (C57BL/6 dorsal skin shaving + MT-II 100 µg/kg s.c. daily × 14d): skin reflectance (L* CIE 1976 colour space): L* decrease −8.4±0.6 vs −0.8±0.2 vehicle (p<0.001); Fontana-Masson silver staining melanin density: stratum basale +38–44%. Photoprotection research: MT-II pre-conditioning before UV-B challenge (30 mJ/cm²): sunburn cell (apoptotic keratinocyte) count −22–28%; CPD formation −18–24% — confirming photoprotective biology beyond simple melanisation.
BPC-157 and Dermal Wound Healing Biology
BPC-157 (15 aa; ~1419 Da) accelerates dermal wound healing through VEGFR2/eNOS/NO angiogenesis, FAK/paxillin keratinocyte migration, and NF-κB/MMP-9 anti-inflammatory suppression. In human keratinocyte (HaCaT) scratch assay: BPC-157 (10 µg/mL): 68–74% closure at 24h vs 38–44% vehicle (FAK-Y397 phosphorylation +1.6–2.0-fold; FAK inhibitor PF-573228 blocks 82% of BPC-157 migration effect). HUVEC tube formation (Matrigel, 16h): total tube length +28–34%; branch points +22–28%. In vivo full-thickness excisional wound (6 mm biopsy punch; C57BL/6): BPC-157 (10 µg/kg i.p. daily): wound closure % at day 7 — 78±4% vs 54±6% vehicle (p<0.001); day 10: 96±2% vs 82±4% (near-complete vs partial); tensile strength (day 14): +18–24% (tensiometry); CD31+ capillary density (HPF): 8.4±0.8 vs 5.6±0.6 (p<0.01); COL1A1 mRNA in wound bed: +22–28% at day 7; MMP-9 wound edge: −28–34%. In aged mouse skin wound model (20-month): BPC-157 partially rescues age-impaired wound healing — closure at day 10: 68±6% vs 48±6% vehicle aged (vs 88±4% young control — partial restoration). These wound healing biology data are distinct from BPC-157's musculoskeletal and gastrointestinal applications.
LL-37 and Skin Innate Immunity
LL-37 is constitutively expressed in the skin epidermis (keratinocytes, sebocytes, eccrine glands, hair follicle bulge stem cells — the primary site of LL-37 production in stress-free skin) and inducibly upregulated by UV, wounding, and bacterial challenge (via vitamin D3/VDR → hCAP18/LL-37 gene transcription; NF-κB via bacterial-driven TLR2/4). In aged skin: LL-37 expression declines −18–28% with advancing age (IHC intensity in epidermis vs young skin biopsies), contributing to increased infection susceptibility and impaired wound response. LL-37 in skin research biology: (1) wound healing — EGFR/Ras/ERK-mediated keratinocyte migration (distinct from FAK/BPC-157 mechanism; additive in combination scratch assay); (2) antimicrobial — S. aureus MIC 2–4 µM in biofilm disruption (MRSA NRS382; MBEC 90% reduction at 8 µM); (3) anti-biofilm — disrupts staphylococcal biofilm matrix (extracellular DNA binding, eDNA degradation facilitation), relevant to chronic wound research models; (4) anti-inflammatory at sub-MIC doses — keratinocyte NF-κB −18–24%, MMP-9 −22–28%, anti-rosacea-relevant; (5) angiogenesis — VEGFR2/EGFR transactivation → HUVEC tube formation +18–24% above control at 0.5 µM (sub-antimicrobial concentration).
Skin Ageing Research Protocol Framework
Skin ageing research requires tissue-appropriate models and validated endpoints. In vitro: primary human dermal fibroblasts (HDFs) from young (20–35 y) vs aged (65+ y) donors — catalogue at ATCC/PromoCell; passage 5–8 for experiments; characterise baseline SA-β-gal%, TERT, COL1A1 to confirm aged phenotype. Keratinocyte: HaCaT (immortalised; UV-challenge model; wound migration) or NHEK primary (normal human epidermal keratinocytes; more physiological). Melanocyte: primary human melanocytes (Caucasian/Type I/II; MC1R functional — critical for MT-II MC1R agonism responses). 3D models: human skin equivalent (HSE; EpiDermFT with dermis; most physiological barrier and wound healing model). In vivo: hairless mouse (SKH-1; standard photoageing model; UV-B chronic irradiation 3× weekly × 12 weeks produces photoageing phenotype); aged C57BL/6 (20–24 months for intrinsic ageing); nude mouse + human skin xenograft (translational but technically demanding). Key endpoints: collagen (Masson trichrome histology; Sircol soluble collagen assay; hydroxyproline; RT-qPCR COL1A1/COL3A1; PICP ELISA); MMP activity (fluorescent MMP-1/3/9 activity assay; zymography); senescence (SA-β-gal, p21/p16 IF, TERT mRNA, telomere FISH); melanogenesis (DOPA oxidase activity; L-DOPA melanin assay; MITF western; reflectance colorimetry L*); wound healing (% closure planimetry; tensile strength; histology granulation/re-epithelialisation); antioxidant (8-OHdG, MDA/TBARS, DHE/DCFH-DA ROS, Nrf2/HO-1 western).
